A simple, linear gradient, rapid, precise and stability-indicating RP-UPLC method was developed for the determination of Cloxacillin Sodium in its bulk form and formulation. Ultra performance liquid chromatography, a most promising advancement in a world of chromatography, reduces analysis time, increases reliability through higher resolution, sensitivity and selectivity as well as used as an economic method due to reducing solvent consumption. A chromatographic separation of a drug as well as its degradants was achieved using Waters acquity BEH, 2.1 3 100 mm, 1.7 mm C 18 column with gradient of mobile phase A: phosphate buffer, pH 6.8 and mobile phase B: methanol:acetonitrile (75:25). The drug and degradants were monitored at a detection wavelength of 225 nm with a flow rate of 0.35 mL/min and an injection volume of 10 mL. The temperature of the column and auto sampler compartments was at 308 8 8 8 8C and 258 8 8 8 8C + + + + + 18 8 8 8 8C, respectively. The retention time of the drug was ∼6.9 min. The resolution of the drug and degradant peak was >1.5 in all cases. Force degradation of CLOX SOD was carried under alkaline, acidic, oxidative, thermal, photo degradation conditions and it was analyzed by the proposed method. The drug degrades under alkaline, acidic and oxidative conditions but was stable in temperature and light. A developed method was validated as per ICH guidelines using validation parameters such as precision, linearity and range, limit of quantification, specificity, assay and robustness.
Introduction
Cloxacillin, chemically known as monosodium(2S,5R,6R)-6-[o-(2-chlorophenyl)-5-methyl-4-isoxazole carboxamido]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo-[3.2.0]-heptane-2-carboxylate monohydrate, is a semi-synthetic antibiotic in the same class as penicillin. It used against staphylococci that produce b-lactamase (1). The chemical structure of Cloxacillin Sodium is depicted in Figure 1 . The ACQUITY ultra performance liquid chromatography (UPLC) system eliminates significant time and cost per sample from an analytical process while improving the quality of the results. What differentiates the system's holistic design is Waters' patented sub-2-mm hybrid particle chemistry, which offers significant benefits over today's high performance liquid chromatography (HPLC) systems equipment. These particles operate at elevated mobile phase linear velocities to affect which cause increase in resolution, sensitivity and speed of analysis. Because of its speed and sensitivity, this technique has gained considerable attention in recent years for pharmaceutical and biomedical analysis (2) (3) (4) (5) (6) . A literature survey reveals that few spectrophotometric and HPLC methods were available for the estimation of Cloxacillin Sodium individually as well as in combination with other drugs. No analytical method was reported for estimation of Cloxacillin Sodium by UPLC in bulk and pharmaceutical dosage form (7 -16) . Hence, it was thought worthwhile to develop and validate the stability-indicating RP-UPLC method for determination of Cloxacillin Sodium in its bulk form and formulation.
Experimental
Chemicals API (CLOX SOD-99.8% Purity) was supplied by Centuarian Laboratories, GIDC, Vadodara, India. Capsules (CLOXI-500 mg) were obtained from Savorite Pharmaceuticals, Alkapuri, Vadodara, India. Methanol (HPLC grade) and sodium hydroxide pellets (AR Grade) were obtained from Finar Reagent, Ahmedabad, India. Furthermore, acetonitrile (HPLC grade) was obtained from Sigma-Aldrich, and H 2 O 2 (30% v/v), HCl and NaOH were obtained from Merck Specialties Pvt Ltd, Ahmedabad, India. Potassium dihydrogen orthophosphate (AR Grade) was obtained from Fluka Reagent, Vadodara, India.
Chromatographic conditions and equipment LC was carried out on a Waters Acquity UPLC with a photodiode array detector. For optimization of chromatographic conditions, the effects of various method parameters such as mobile phase, column, flow rate and solvent ratio were studied and the chromatographic parameters such as asymmetric factor, resolution and column efficiency were calculated. The separation was achieved on an Acquity H-UPLC C18 100 mm Â 2.1 mm, BEH 1.7 mm column using mobile phase A: 20 mM phosphate buffer, pH 6.8, and mobile phase B: methanol:acetonitrile (75:25) using a gradient program. The drug and degradation products were detected (see Table I ). By keeping the column temperature of 308C, flow rate of 0.35 mL/min and injection volume of 10 mL, all peaks were separated, and the gradient pattern did not interfere with the CLOX SOD peak which was detected by a PDA detector at 225 nm.
Preparation of solutions
An accurately weighed 50 mg of CLOX SOD API was transferred into a 100 mL-volumetric flask. First, it was dissolved in 50 mL buffer and sonicated, then diluted up to the mark with buffer to get the concentration of CLOX SOD (500 mg/mL). Concentrations ranging from 0.025 to 75 mg/mL for CLOX SOD were prepared from stock solution and different validation parameters were performed.
Validation procedure
Validation of the newly developed method was studied in terms of linearity and range, precision, accuracy, robustness, limit of detection (LOD) and limit of quantification (LOQ) as per the ICH guidelines (17) . For linearity, the solutions were prepared from the stock solution (500 mg/mL) ranging from 0.025 to 75 mg/mL, the calibration curve was generated, and regression parameters were obtained. The LOQ was estimated from the set of five calibration curves of CLOX SOD. The precision of the method was studied by checking the repeatability, interday and intraday precision for three concentrations thrice. Accuracy of the method was determined by calculating percentage recoveries of CLOX SOD by the standard addition method. A known amount of standard solutions of CLOX SOD (0.025, 50 and 75 mg/mL) was added to a preanalyzed sample solution of CLOX SOD (50 mg/mL). Robustness of the method was studied by changing the temperature of column compartment by +5 units and flow rate by +5 mL/min. The changes in the response of CLOX SOD were noted and compared with the original one. System suitability parameters are mentioned in Table II .
Specificity-forced degradation studies
To prove the stability-indicating property of the method, forced degradation studies were performed on CLOX SOD. For acid degradation, 2 mL of standard stock solution (500 mg/mL) was added to a 20-mL volumetric flask and to this 2 mL of 0.1 N HCl solution was added and kept at room temperature for 30 min. Then, 2 mL of 0.1 N NaOH was added to neutralize it and the volume was made up by buffer solution to make a final concentration of 50 mg/mL. For base degradation, 2 mL of standard stock solution (500 mg/mL) was added to a 20-mL volumetric flask. To this solution, 2 mL of 0.05 N NaOH solution was added and the solution was kept at room temperature for 5 min. Then, 2 mL of 0.05 N HCl was added to neutralize it and the volume was made up by buffer solution to make a final concentration of 50 mg/mL. For oxidation degradation, 2 mL of standard stock solution (500 mg/mL) was added to 20 mL of the volumetric flask and to this solution, 2 mL of 0.03% hydrogen peroxide was added. This solution was kept for 1 h at room temperature. The volume was made up by buffer to make a final concentration of 50 mg/mL. For thermal degradation, 50 mg/mL solution of CLOX SOD (working standard) was exposed to 608C for 3 days. As well as API of CLOX SOD was also exposed to the same condition for 3 days and the photo degradation was done by prepared 50 mg/mL solution of CLOX SOD (working standard) was exposed to 200 lux h for 3 days.
Results and Discussion

UPLC method development
The main aim of the chromatographic method was to achieve separation of degradation products in the presence of drug substance. CLOX SOD was soluble in water. Practically, the solubility of CLOX SOD was observed in alcohol and water. The diluent selected in the finalized method was phosphate buffer, pH 6.8, as it was found compatible with the mobile phase. The pK a of CLOX SOD was reported as 2.79. Therefore, the pH of the mobile phase was selected on the basis of pK a . Initially, isocratic HPLC conditions were optimized for CLOX SOD but degradation products were not separated properly in HPLC and CLOX SOD was eluted late. Therefore, the gradient system is used to reduce run time and due to less particle size in UPLC, it gives more separation of degradation products. It is also observed that the elution time of CLOX SOD in UPLC was reduced 10-fold to that of HPLC. Therefore, using the UPLC method instead of the HPLC method gives good resolution and also reduces tailing of drug substance. The objective of the study to develop and validate the stability-indicating RP-UPLC method for determination of Cloxacillin Sodium in its bulk form and formulation was accomplished using the Acquity H-UPLC C18 100 mm Â 2.1 mm, BEH 1.7 mm column with PDA detection at 225 nm. Initially, various mobile phase compositions were tried to elute complex but mobile phase comprising of mobile phase A: 20 mM phosphate buffer, pH 6.8, and mobile phase B: methanol:acetonitrile (75:25 v/v) was found to be giving better resolution with a run time of 13 min and a flow rate 0.35 mL/min. The retention time was found to be 6.9 min.
Specificity
The forced degradation studies were performed to check the possible degradation of the active pharmaceutical ingredient when exposed to various conditions such as acidity, alkalinity and thermal conditions. The analytical method was used to measure the analyte response in the presence of its degradation products. The degradation results for all the stress conditions are discussed (see Table III ). From the chromatograms of degradation under different conditions, we concluded that CLOX SOD was stable in temperature and light (see Figures 2-6 ). The purity of the principle and other chromatographic peaks was found to be satisfactory which confirmed the stability-indicating power of the UPLC method.
Linearity and range
Linearity was determined by preparing solutions over the range of 0.05-150% of the assay concentration. Linear correlation was obtained between the peak area versus concentration of CLOX SOD. The linearity was observed in the range of 0.025-75 mg/mL. The R 2 obtained was 0.998. The regression results suggested an excellent correlation between the peak area and concentration values (see Table IV ).
LOQ
The LOQ was estimated from the set of five calibration curves (see Table IV ).
The LOQ was calculated by using the formula
where SD, is the standard deviation of the response and S is the slope of calibration curve of the analyte.
Precision
The precision of the proposed method was determined by carrying out repeatability and intermediate studies. The repeatability was checked by repeatedly (n ¼ 6) injecting sample solutions and computing the relative standard deviation (% RSD) of the assay results. The % RSD observed was 0.08, which was well within the acceptance criteria and the study concludes repeatability of the method. The method precision was repeated on a different day, by a different analyst, using a different UPLC system. The % RSD was calculated and found to be 0.9%, which was within the limit of 2%. Hence, the method is precise and rugged (see Table V ).
Accuracy
The accuracy of the method was determined for the CLOX SOD by spiking its stock solution in a blank matrix in triplicate at levels 50, 100 and 150% of the specified limit. The mean % recovery at the 50, 100 and 150% level was found to be 101.2, 100.0 and 101.4, respectively, and % RSD was found to be 1.0, 0.7 and 0.5, respectively, which meets the established acceptance criteria. Thus, the study proves that the method is accurate in the considered range (Table V) .
Assay
Analysis of samples of marketed antibiotic capsules containing 500 mg of CLOX SOD was carried out, and the amount recovered was found to be 99.1 (Table VI and Figure 7 ). % Assay CLOX SOD was within the acceptance range of 98 -102%.
Robustness
To prove the reliability of the analytical method during the normal usage, some small but deliberate changes were made in the analytical method. The robustness of the method was studied by changing the flow rate (0.30, 0.35 and 0.40 mL/min), and the column oven temperature (25, 30 and 358C), the retention time, theoretical plates, asymmetry factor were observed. Theoretical plates and asymmetry values were obtained from the first injection of the system suitability set and were found well within the acceptance criteria. Thus, the study proves the reliability of the test method for minor changes under chromatographic conditions. Hence, the method can be termed as robust (Table VII) .
Conclusion
The new stability-indicating method for determination of Cloxacillin Sodium in bulk and marketed formulations was developed and validated. In this method, the use of RP-UPLC helped in giving faster retention time and better resolution of peaks than that of HPLC. Hence this method exhibited excellent performance in terms of sensitivity and speed. The method was fully validated, showing satisfactory data for all the parameters tested. There were no common degradation products for Cloxacillin Sodium in all degradation conditions.
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